As per Future Market Insights, surgical technology and biologics companies that have the capability to provide procedure-ready hemostatic and sealing adjuncts that are aligned with standardized vascular and cardiovascular procedures are driving the market. There is a transition being noticed from a focus on suturing and mechanical closure to bioactive and synthetic sealants that are intended for rapid hemostatic control and controlled tissue sealing at high-risk anastomotic interfaces.